The Ubiquitous Mineralocorticoid Receptor: Clinical Implications
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Mineralocorticoid receptors (MR) exist in many tissues, in which they mediate diverse functions crucial to normal physiology, including tissue repair and electrolyte and fluid homeostasis. However, inappropriate activation of MR within these tissues, and especially in the brain, causes hypertension and pathological vascular, cardiac, and renal remodeling. MR binds aldosterone, cortisol and corticosterone with equal affinity. In aldosterone-target cells, co-expression with the 11β-hydroxysteroid dehydrogenase 2 (HSD2) allows aldosterone specifically to activate MR. Aldosterone levels are excessive in primary aldosteronism, but in conditions with increased oxidative stress, like CHF, obesity and diabetes, MR may also be inappropriately activated by glucocorticoids. Unlike thiazide diuretics, MR antagonists are diuretics that do not cause insulin resistance. Addition of MR antagonists to standard treatment for hypertension and cardiac or renal disease decreases end-organ pathology and sympathetic nerve activation (SNA), and increases quality of life indices.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214 · cited 12×
“Both angiotensin II and aldosterone are increased in congestive heart failure (CHF), and the persistent elevation of both has clearly deleterious consequences on cardiac and vascular structures.”
InfluentialPitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
Eplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111
Brain corticosteroid receptor balance in health and disease
de Kloet, E. R., Vreugdenhil, E., Oitzl, M. S., & Joëls, M. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.3.0331 · Cited by 2,614
Brain corticosteroid receptor balance in health and disease
de Kloet, E. R. (1998) · Endocrine Reviews · doi:10.1210/er.19.3.269 · Cited by 2,614
Two receptor systems for corticosterone in rat brain: Microdistribution and differential occupation
REUL, J. M. H. M., & KLOET, E. R. D. (1985) · Endocrinology · doi:10.1210/endo-117-6-2505 · Cited by 2,580
Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study
Juurlink, D. N., Mamdani, M. M., Lee, D. S., Kopp, A., Austin, P. C., Laupacis, A., & Redelmeier, D. A. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040135 · Cited by 1,761
Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated
Funder, J. W., Pearce, P. T., Smith, R., & Smith, A. I. (1988) · Science · doi:10.1126/science.2845584 · Cited by 1,628 · cited 1×
“Specificity of the MR for aldosterone in transporting epithelia was found to be due to the co-expression of an enzyme, 11β-hydroxysteroid dehydrogenase 2 (11βHSD2), which metabolizes the active glucocorticoids cortisol and corticosterone to the inactive metabolites cortisone and 11-dehydrocorticosterone [21–23].”
The coming out of the brain mineralocorticoid receptor
Joëls, M., Karst, H., DeRijk, R., & de Kloet, E. R. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2007.10.005 · Cited by 481 · cited 1×
“In tissues that do not express the 11β-HSD2, such as the cardiomyocyte and specific neurons in the brain [24–26], cortisol or corticosterone occupy the receptor almost entirely.”
Effectiveness of Aldosterone Blockade in Patients With Diabetic Nephropathy
Sato, A., Hayashi, K., Naruse, M., & Saruta, T. (2003) · Hypertension · doi:10.1161/01.hyp.0000044937.95080.e9 · Cited by 466 · cited 1×
“Current recommendations for the treatment of hypertensive diabetics include the use of ACEi or ARB to block the renin-angiotensin system; however, in diabetics with proteinuria incompletely corrected with an ACEi, the addition of spironolactone has clear additive effects on decreasing protein excretion, with an additi…”
Cited by
A General Introduction to Glucocorticoid Biology
Timmermans, S., Souffriau, J., & Libert, C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01545 · Cited by 609
The multifaceted mineralocorticoid receptor
Gomez‐Sanchez, E., & Gomez‐Sanchez, C. E. (2014) · Comprehensive Physiology · doi:10.1002/j.2040-4603.2014.tb00569.x · Cited by 55
Self-citationExtrarenal Effects of Aldosterone on Potassium Homeostasis
Palmer, B. F., & Clegg, D. J. (2022) · Kidney360 · doi:10.34067/kid.0006762021 · Cited by 40
Metadata
- Authors
- Hawkins, U. A., Gomez-Sanchez, E. P., Gomez-Sanchez, C. M., & Gomez-Sanchez, C. E.
- Venue
- Current Hypertension Reports
- Published
- 2012-07-29
- Volume
- 14
- Issue
- 6
- Pages
- 573-580
- ISSN
- 1522-6417 (ISSN-L)
- 1534-3111
- OpenAlex
- W2058070019
- Cited by
- 112
- References
- 16
- FWCI
- 4.60
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Ubiquitous Mineralocorticoid Receptor: Clinical Implications. https://app.cochat.ai/papers/10.1007/s11906-012-0297-0
- The paper
- Hawkins, U. A., Gomez-Sanchez, E. P., Gomez-Sanchez, C. M., & Gomez-Sanchez, C. E. (2012). The Ubiquitous Mineralocorticoid Receptor: Clinical Implications. Current Hypertension Reports. https://doi.org/10.1007/s11906-012-0297-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.